The net outflow of the main market exceeded 10 billion.The application direction of AI fell in early trading, with Jincai Internet falling more than 8%, followed by Tianyu Digital, Huayang Lianzhong, Fushi Holdings, Aofei Entertainment and Fengyuzhu.The T-shaped overpass with the longest and heaviest single span in China successfully turned and crossed Panxi Railway. According to The Paper, on the afternoon of December 11th, after 82 minutes of continuous construction, the T-shaped overpass with the longest and heaviest single span in China turned 52 degrees clockwise from Panxi Railway Vehicle Turning Station to Yangweishao Station under the jurisdiction of Kunming Bureau of China Railway, realizing a "gorgeous turn" and successfully completed the turn across Panxi Railway.
Southern Power Grid: In November, the installed capacity of industrial and commercial distributed photovoltaic projects was newly put into operation, with more than 500 MW. Southern Power Grid (003035) said at the institutional investor strategy meeting on December 12 that in 2024, the company will continue to give full play to the advantages of distributed photovoltaic energy-saving track, focusing on key industries with good industry prospects, strong sustainable operation ability and large electricity consumption, and increase development efforts. According to preliminary statistics, from January to November 2024, the installed capacity of industrial and commercial distributed photovoltaic projects was newly put into operation with more than 500 MW.HKEx: The database of integrated fund platform funds was launched, and the database of integrated fund platform funds was announced by HKEx, covering more than 2,000 funds approved by the Hong Kong Securities Regulatory Commission, aiming at improving the information transparency of Hong Kong fund investment products.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)
Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)Japan's Topix index fell to 1%.In the exchange market, the national debt rose the most, with "National Debt 2404" rising more than 4%, "National Debt 23", "Special Country 24 03" and "Special Country 24 01" rising nearly 1%.
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide